Full-Time

CMC Project Leader

Bachem

Bachem

1,001-5,000 employees

Develops and manufactures peptides and oligonucleotides

Compensation Overview

$108.6k - $149.3k/yr

+ Bonus

Carson, CA, USA

In Person

Category
Business & Strategy (1)
Required Skills
SharePoint
Forecasting
SAP Products
Salesforce
REST APIs

Get referred to Bachem

See people who can refer or advise you

Requirements
  • Bachelor's Degree in Science (Chemistry, Biochemistry, Bioengineering or similar field)
  • Master's Degree in Science (Chemistry, Biochemistry, Bioengineering, or similar) field referred or
  • Master's Degree MBA, PMP, or similar certification preferred or
  • PhD in Science (Chemistry, Biochemistry, Bioengineering, or similar) field preferred or
  • Minimum 6 years' experience of (bio-)pharma/CDMO/chemical industry with bachelor's degree required or
  • Minimum 4 years' experience of (bio-)pharma/CDMO/chemical industry with master's degree required
  • Minimum 2 years' experience in customer-facing role or CMC project management required
  • Have basic knowledge of clinical development (phases, key goals, requirements) and associated regulatory compliance/filings for drug substances. Basic understanding of GMP required
  • Experience with different types of customers (small/biotech and large) with a basic understanding of GMP preferred
  • Ability to understand financial aspects of customer accounts (Payment terms, pre-payment requirements, forecasting)
  • Familiarity with drug substance characterization analysis (HPLC, UPLC, LC-MS, MS, GC-MS, AAA, CHN) for in-process, release, and stability testing
  • Excellent computer/system skills, especially MS Office, CRM (Salesforce), Document Control (Master Control), Document-sharing (SharePoint, ShareFile), ERP (SAP) or CRM, MS Project
  • Demonstrated ability to effectively organize, multitask, and thrive in a fast-paced, deadline-driven environment. Skilled in proactive, solution-focused communication, ensuring management and stakeholders are informed of potential issues. Detail-oriented with strong problem-solving skills, capable of working independently and managing time efficiently. Excellent communicator with the ability to collaborate effectively in cross-functional team settings.
  • Knowledge of Chemistry, Manufacturing, and Controls (CMC) documents having to do with IND and NDA filings and API development
  • Knowledge of contracts and agreements (NDA’s, Supply Agreements, Quality Agreements, Request for Proposals) to ensure they are adhered to during project execution
  • Certified Project Management Professional (PMP)-PMI preferred

Bachem provides development and manufacturing of peptides and oligonucleotides for research, clinical development, and commercial products. Its offerings include custom synthesis and scale-up production, analytical testing, and related services across the drug development spectrum. Customers work with Bachem by specifying desired sequences and specifications, after which Bachem designs, synthesizes, and quality-controls the peptides or oligonucleotides and delivers them in appropriate scales and formats. The company differentiates itself through more than five decades of experience, a global footprint with sites in Europe, the US, and Asia, and an integrated set of services spanning discovery support to commercial manufacturing. Its goal is to help pharmaceutical and biotechnology companies advance peptide- and oligonucleotide-based therapies by providing reliable, scalable, and well-supported manufacturing and development capabilities.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bubendorf, Switzerland

Founded

1971

Get referred to Bachem

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The CHF 500 million Sisslerfeld investment expands peptide capacity for sustained demand.[1][2]
  • A five-year CHF 500 million credit facility supports expansion with added financing flexibility.
  • New biotech contracts, including ImmuPharma Kapiglucagon, reinforce Bachem's API development pipeline.
  • CEO Anne-Kathrin Stoller and COO Hans Van Hees strengthen operational continuity during scaling.

What critics are saying

  • Sisslerfeld production starts only in 2030, leaving years of execution risk.
  • Undisclosed partnership terms create counterparty risk if demand or commitments weaken.[1][2]
  • Heavy capital spending can strain margins if utilization, hiring, or commissioning lag.

What makes Bachem unique

  • Bachem specializes in peptides and oligonucleotides across research, clinical, and commercial supply.[1]
  • Its global manufacturing network spans Switzerland, the United States, the United Kingdom, and Asia.[1][3]
  • The Sisslerfeld greenfield plant is tied to long-term supply commitments and advance payments.[1][2]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Growth & Insights and Company News

Headcount

6 month growth

23%

1 year growth

23%

2 year growth

23%
ImmuPharma PLC
Jun 25th, 2026
ImmuPharma appoints Bachem as API manufacturing partner for Kapiglucagon.

ImmuPharma appoints Bachem as API manufacturing partner for Kapiglucagon. ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that, following a competitive tender process, it has appointed Bachem AG ("Bachem") as manufacturing partner for the active pharmaceutical ingredient ("API") for its Kapiglucagon program. Bachem is a leading global peptide and oligonucleotide development and manufacturing partner, supporting pharmaceutical and biotechnology companies from early-stage development through to commercial supply. The appointment represents an important Chemistry, Manufacturing and Controls ("CMC") milestone and is expected to support the next stage of pharmaceutical development and IND-enabling preparation for Kapiglucagon. About Kapiglucagon Kapiglucagon is a proprietary glucagon prodrug being developed for Type 1 diabetes ("T1D") applications, with a focus on overcoming the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings. ImmuPharma believes Kapiglucagon represents an important strategic opportunity alongside its lead asset, P140. The Company has previously stated that it intends to evaluate a 505(b)(2) regulatory pathway in the United States, leveraging existing data on native glucagon, subject to FDA confirmation. Next steps The immediate CMC focus will be the API workstream with Bachem, followed by the selection and appointment of a drug product ("DP") manufacturing partner to support formulation, manufacturing and broader IND-enabling activities. In parallel, ImmuPharma will continue to advance the regulatory and development strategy for Kapiglucagon, including future regulatory interactions and, subject to alignment with health authorities, progression towards IND submission and first-in-human studies. Dr Sébastien Goudreau, Chief Scientific Officer of ImmuPharma, said: "We are pleased to appoint Bachem as API manufacturing partner for Kapiglucagon. This is an important CMC step for the program and strengthens the foundation for its further development toward the clinic."

Nordic Life Science
Nov 18th, 2025
TIRmed Pharma collaborates with Bachem

TIRmed Pharma collaborates with Bachem. The collaboration includes process development and manufacturing of TIR-01, the active substance in TIRmed's treatment for atopic dermatitis (eczema), and marks an important step towards future clinical trials. As part of its preclinical program, TIRmed Pharma is collaborating with Bachem to establish high-quality production processes for TIR-01, an oligonucleotide-based compound, they describe in a press release. With its expertise in oligonucleotide production, Bachem provides critical expertise for GMP development, ensuring stability, consistency and regulatory compliance for upcoming clinical studies according to the company. "The collaboration with Bachem is an important milestone in the work of taking our drug candidate further towards the clinic," says Leo Holmgren, CEO of TIRmed Pharma. "It gives us access to world-leading manufacturing expertise and strengthens the foundation for being able to offer patients a longer-term treatment alternative," he adds. Learn more about the science behind TIRmed Pharma and its connections to this year's Nobel Prize in Medicine in our latest issue of the magazine - out now!

CHEManager
Oct 31st, 2025
Anne-Kathrin Stoller Becomes New CEO at Bachem

Anne-Kathrin Stoller becomes new CEO at Bachem. Bachem announced today that the Board of Directors has appointed Anne-Kathrin Stoller, the former Head of Bachem Americas and previously the company's CMO for many years, as the new CEO effective january 1, 2026. She succeeds Thomas Meier, who has decided to take on a new challenge outside the company after more than thirty years at Bachem and almost six years as CEO. "Thomas Meier has contributed significantly to Bachem's continued success. Together with his team, he has achieved a capital-efficient and profitable growth. At the same time, Bachem's position as an innovative and reliable partner to the pharmaceutical industry has been further strengthened. We would like to express our sincere thanks to Thomas for his many years of service, his leadership and extraordinary contribution to Bachem," says Kuno Sommer, Chairman of the Board of Directors of Bachem. He continues: "I am very pleased that we have been able to appoint Anne-Kathrin Stoller, an experienced and competent successor from within our own ranks, as the new CEO. Anne-Kathrin has an excellent combination of expertise, leadership skills, and customer focus and, together with her colleagues in the Executive Committee, will continue Bachem's successful course." Thomas Meier, CEO, Bachem, added: "Bachem is a great company and has developed into a leading global, innovation-driven developer and manufacturer of peptides and oligonucleotides in recent years. I have had the privilege of helping to shape and accompany this development in various roles over the past three decades, and I am very grateful for the many enriching experiences I have had at work and the formative encounters with people. Above all, I would like to thank Bachem's employees and customers, as well as my colleagues in the Executive Committee and on the Board of Directors, for their active support and excellent cooperation." Anne-Kathrin Stoller, current Head of Bachem Americas and future CEO, Bachem, commented: "I am delighted to have earned the trust of the Board of Directors and will do everything in my power, together with the members of the Executive Committee and all Bachem employees, to continue our company's impressive success story. Under the leadership of Thomas Meier, Bachem has set the course for the future. I would like to thank him for his collegial support over the past years and everyone at Bachem who works hard every day to ensure that we make an important contribution to human health." Anne-Kathrin Stoller has worked for Bachem since 2006. After holding various management positions, including Head of Business Development & Sales Europe, Chief Marketing Officer and member of the Group Executive Board, she took on the role of Chief Operating Officer Americas in 2022 and is responsible for the company's US business. Anne-Kathrin Stoller studied chemistry in Hanover and Cambridge (UK) and holds a doctorate in bioorganic chemistry from the University of Basel.

Stock Titan
Aug 20th, 2025
Bachem Expands Corporate Executive Committee to Include Chief Operations Officer Role

Bachem (OTC:BCHMY) has announced the appointment of Hans Van Hees as Chief Operations Officer (COO), effective September 1, 2025.

Stock Titan
Jul 24th, 2025
Bachem Shows Strong Growth in the First Half of 2025

Looking ahead, Bachem aims to achieve annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026, supported by significant investments including the new Building K facility and planned expansion in Sisslerfeld.